Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Sales | 18,960 | 17,454 | 13,651 | 8,709 | 7,345 |
| Gross Profit | 18,960 | 17,454 | 13,651 | 8,709 | 7,345 |
| Operating Expenses | 125,471 | 132,887 | 120,327 | 101,159 | 117,373 |
| Operating Income | -106,511 | -115,433 | -106,676 | -92,450 | -110,028 |
| Other Income | -779 | 2,499 | 2,605 | 2,321 | 7,054 |
| Pre-tax Income | -107,290 | -112,934 | -104,071 | -90,129 | -102,974 |
| Net Income Continuous | -107,290 | -112,934 | -104,071 | -90,129 | -102,974 |
| Net Income | $-107,290 | $-112,934 | $-104,071 | $-90,129 | $-102,974 |
| EPS Basic Total Ops | -1.25 | -1.32 | -1.21 | -1.05 | -1.21 |
| EPS Basic Continuous Ops | -1.25 | -1.32 | -1.21 | -1.05 | -1.21 |
| EPS Diluted Total Ops | -1.25 | -1.32 | -1.21 | -1.05 | -1.21 |
| EPS Diluted Continuous Ops | -1.25 | -1.32 | -1.21 | -1.05 | -1.21 |
| EBITDA(a) | $-103,511 | $-112,415 | $-103,176 | $-88,439 | $-105,427 |